A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV
ConclusionThese results indicate that coadministration of islatravir and doravirine had no clinically meaningful effect on the pharmacokinetics of either drug, and support further clinical investigation of islatravir in combination with doravirine for the treatment of HIV-1 infection. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 21, 2021 Category: Drugs & Pharmacology Source Type: research

Blister-Packing of 2 mg Buprenorphine Monoproduct as a Patient-Centered Method of Microdosing for Buprenorphine Induction
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 14, 2021 Category: Drugs & Pharmacology Source Type: research

Relative Bioavailability of Omecamtiv Mecarbil Pediatric Minitablet Formulations in Healthy Adult Subjects
ConclusionsRelative bioavailability of slow-release minitablets was demonstrated to be similar to the adult matrix MR formulation. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 10, 2021 Category: Drugs & Pharmacology Source Type: research

Spontaneous and Immune Checkpoint Inhibitor-Induced Autoimmune Diseases: Analysis of Temporal Information by Using the Japanese Adverse Drug Event Report Database
ConclusionsThis paper describes risk profiles with temporal information of ICI-induced ADs and proposes certain indicators for deciphering the mechanism of AD onset. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 10, 2021 Category: Drugs & Pharmacology Source Type: research

Response to “Comment on: Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety”
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 10, 2021 Category: Drugs & Pharmacology Source Type: research

Successful Intravenous Thrombolysis and Endovascular Treatment for Acute Ischemic Stroke in a Patient Pretreated with Ticagrelor: A Case Report and Literature Review
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 9, 2021 Category: Drugs & Pharmacology Source Type: research

Buprenorphine Microinduction: Logistical Barriers and the Need for Convergent Evidence
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 9, 2021 Category: Drugs & Pharmacology Source Type: research

Prehospital Adenosine Diphosphate Receptor Blocker Use, Culprit Artery Flow, and Mortality in STEMI: The MADDEC Study
AbstractBackground and ObjectiveThe newer adenosine diphosphate (ADP) receptor blockers ticagrelor and prasugrel are superior to clopidogrel in the long-term management of acute coronary syndrome (ACS). We evaluated the acute performance (prehospital loading) of these ADP receptor blockers in a primary percutaneous coronary intervention (PCI) for an ST-elevation myocardial infarction (STEMI).MethodsIn a retrospective, single-center registry study, data on all STEMI patients admitted for their first primary PCI between January 2007 and April 2020 were analyzed (n = 3218). The three ADP receptor blockers were mainl...
Source: Clinical Drug Investigation - June 8, 2021 Category: Drugs & Pharmacology Source Type: research

Effect of Omecamtiv Mecarbil on the Pharmacokinetics of Metformin, a Probe Substrate for MATE1/MATE2-K, in Healthy Subjects
ConclusionsThere was no clinically relevant effect of OM on the pharmacokinetics of metformin in healthy subjects. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 7, 2021 Category: Drugs & Pharmacology Source Type: research

Correction to: Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges
A correction to this paper has been published: https://doi.org/10.1007/s40261-021-01053-2 (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - June 5, 2021 Category: Drugs & Pharmacology Source Type: research

Dose-Ranging and Cumulative Dose Studies of Albuterol Sulfate MDI in Co-Suspension Delivery ™ Technology (AS MDI; PT007) in Patients with Asthma: the ASPEN and ANTORA Trials
AbstractBackground and ObjectivesCo-suspension Delivery ™ Technology has been developed for the administration of albuterol sulfate pressurised inhalation suspension via metered-dose inhaler (AS MDI, PT007). We assessed the efficacy and safety of AS MDI versus Proventil® in order to determine the optimal dose of AS MDI to take to Phase III clinical trials.MethodsASPEN (NCT03371459) and ANTORA (NCT03364608) were Phase II, randomised, crossover, multicentre studies of AS MDI versus Proventil® in patients with persistent asthma. In ASPEN, 46 patients received cumulative-dose treatments (90 μg/inhalation using...
Source: Clinical Drug Investigation - June 4, 2021 Category: Drugs & Pharmacology Source Type: research

Comment on ‘Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety’
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - May 26, 2021 Category: Drugs & Pharmacology Source Type: research

Real-world Prescription Pattern, Discontinuation and Costs of Ibrutinib-Na ïve Patients with Chronic Lymphocytic Leukemia: An Italian Healthcare Administrative Database Analysis
ConclusionsThis analysis on Italian administrative data provided results about prescription patterns of ibrutinib FL and SLL new users with CLL, focusing on discontinuation, treatment change and healthcare costs over 2-year follow-up, and contributed to improve the knowledge on this hard-to-treat disease. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - May 25, 2021 Category: Drugs & Pharmacology Source Type: research

New Models for the Evaluation of Specialized Medicinal Products: Beyond Conventional Health Technology Assessment and Pricing
The objectives of this article are to discuss why the current HTA process is inadequate for evaluating these new therapies, how evidence should be continuously generated and presented to regulators and payers to support their use, and to propose new approaches to pricing models. This will enable payers to have an affordable, risk-mitigated means of funding new therapies in a timely manner, thus guaranteeing patient access to new, potentially life-saving therapies, while providing manufacturers with a return on their investment. Without new approaches or adaptation of existing frameworks, certain ATMPs may not reach patient...
Source: Clinical Drug Investigation - May 20, 2021 Category: Drugs & Pharmacology Source Type: research

Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial
ConclusionCo-administration of 60 mg atogepant with 1000 mg acetaminophen or 500 mg naproxen was safe and well tolerated in healthy participants, and no DDIs were observed. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - May 5, 2021 Category: Drugs & Pharmacology Source Type: research

First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects
ConclusionSUVN-D4010 was found to be safe and well tolerated in healthy human subjects. SUVN-D4010 followed linear pharmacokinetics across the dose range. Accumulation was in the range of 1.3- to 1.4-fold after multiple dosing. Renal excretion is not the major route of elimination. Food had no effect on the exposures but increased thetmax of SUVN-D4010. Exposures were lower in females and elderly subjects suggesting sex and age effects on the pharmacokinetics of SUVN-D4010 and possible dose adjustment in these populations. SUVN-D4010 was well tolerated and safe in elderly subjects after a single dose.Clinical trial identif...
Source: Clinical Drug Investigation - May 1, 2021 Category: Drugs & Pharmacology Source Type: research

Performance Characteristics of Breezhaler ® and Aerolizer® in the Real-World Setting
AbstractThe evaluation of errors in use with different inhaler devices is challenging to quantify as there are a number of definitions of critical and non-critical errors with respect to inhaler use; in addition, performance characteristics of the device, such as airflow resistance, can also influence effective use in the real-world setting. Repeated observations and checking/correcting inhaler use are essential to optimise clinical effectiveness of inhaled therapy in patients. Breezhaler® is a single unit-dose dry powder inhaler used in chronic obstructive pulmonary disease and in asthma (budesonide) that has low airf...
Source: Clinical Drug Investigation - May 1, 2021 Category: Drugs & Pharmacology Source Type: research

Correction to: Efficacy of Collagenase Clostridium histolyticum (Xiapex ®) in Patients with the Acute Phase of Peyronie’s Disease
A correction to this paper has been published: https://doi.org/10.1007/s40261-021-01037-2 (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - May 1, 2021 Category: Drugs & Pharmacology Source Type: research

Comparison of Pharmacokinetic Profiles of Beraprost Sustained Release in Japanese, Chinese, and Korean Healthy Adult Males
ConclusionsThere were no clinically meaningful ethnic differences in the pharmacokinetics of BPS and BPS-314d following beraprost SR administration among Japanese, Chinese and Korean populations. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - April 28, 2021 Category: Drugs & Pharmacology Source Type: research

Correction to: Decision Analysis: Omadacycline Relative to Moxifoxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difcile Infection
A correction to this paper has been published: https://doi.org/10.1007/s40261-021-01039-0 (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - April 28, 2021 Category: Drugs & Pharmacology Source Type: research

Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies
AbstractBackgroundSolid tumors are a common predisposing factor for invasive candidiasis (IC) or candidemia due to IC.ObjectivesPost hoc analysis of patient-level efficacy and safety data from six studies of anidulafungin (with similar protocols/endpoints) in adults with IC/candidemia summarized by past or recent diagnosis of solid tumors.Patients/methodsPatients received a single intravenous (IV) dose of anidulafungin 200 mg, followed by 100 mg once daily. After ≥ 5 to ≥ 10 days of IV treatment, switch to oral voriconazole/fluconazole was permitted in all but one study. Time of solid tumor diagnosis was de...
Source: Clinical Drug Investigation - April 23, 2021 Category: Drugs & Pharmacology Source Type: research

Riboflavin in Neurological Diseases: A Narrative Review
AbstractRiboflavin is classified as one of the water-soluble B vitamins. It is part of the functional group of flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) cofactors and is required for numerous flavoprotein-catalysed reactions. Riboflavin has important antioxidant properties, essential for correct cell functioning. It is required for the conversion of oxidised glutathione to the reduced form and for the mitochondrial respiratory chain as complexes I and II contain flavoprotein reductases and electron transferring flavoproteins. Riboflavin deficiency has been demonstrated to impair the oxidative state ...
Source: Clinical Drug Investigation - April 22, 2021 Category: Drugs & Pharmacology Source Type: research

Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections
ConclusionsIn this experience, the use of dalbavancin contributed to shorten LOS and treatment-related costs, especially in difficult Gram-positive infections requiring prolonged therapy. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - April 21, 2021 Category: Drugs & Pharmacology Source Type: research

Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
A correction to this paper has been published: https://doi.org/10.1007/s40261-021-01036-3 (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - April 20, 2021 Category: Drugs & Pharmacology Source Type: research

Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China
ConclusionsT-DM1, as second-line therapy in the treatment of HER2-positive breast cancer, is not a cost-effective option in China. Given the significant clinical efficacy, an appropriate price reduction of T-DM1 is required to benefit more HER2-positive breast cancer patients. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - April 20, 2021 Category: Drugs & Pharmacology Source Type: research

Lung Function Normalisation with Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Asthma
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - April 17, 2021 Category: Drugs & Pharmacology Source Type: research

Correction to: Efficacy of Collagenase Clostridium histolyticum (Xiapex ® ) in Patients with the Acute Phase of Peyronie’s Disease
A correction to this paper has been published: https://doi.org/10.1007/s40261-021-01037-2 (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - April 17, 2021 Category: Drugs & Pharmacology Source Type: research

Long-Term Survival of Over 6  Years with Afatinib Sequential Treatment in a Patient with EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Case Report
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - April 16, 2021 Category: Drugs & Pharmacology Source Type: research

Authors ’ Reply to ‘Comment on: Bempedoic Acid and Ezetimibe for the Treatment of Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials’
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - April 11, 2021 Category: Drugs & Pharmacology Source Type: research

Comment on ‘Bempedoic Acid and Ezetimibe for the Treatment of Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Phase II/III trials’
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - April 7, 2021 Category: Drugs & Pharmacology Source Type: research

The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
AbstractAlthough expanding the availability of buprenorphine —a first-line pharmacotherapy for opioid-use disorder (OUD)—has increased the capacity of healthcare systems to offer treatment, starting this medication is fraught with significant barriers. Standard induction regimens require persons with OUD to taper and discontinue full opioid agonists and e xperience opioid withdrawal prior to the first dose of buprenorphine. Further, emerging evidence indicates that precipitated withdrawal during induction may impact long-term treatment outcomes. Microinduction is a novel approach that, by harnessing buprenorphi...
Source: Clinical Drug Investigation - April 5, 2021 Category: Drugs & Pharmacology Source Type: research

First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT 4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects
ConclusionSUVN-D4010 was found to be safe and well tolerated in healthy human subjects. SUVN-D4010 followed linear pharmacokinetics across the dose range. Accumulation was in the range of 1.3- to 1.4-fold after multiple dosing. Renal excretion is not the major route of elimination. Food had no effect on the exposures but increased thetmax of SUVN-D4010. Exposures were lower in females and elderly subjects suggesting sex and age effects on the pharmacokinetics of SUVN-D4010 and possible dose adjustment in these populations. SUVN-D4010 was well tolerated and safe in elderly subjects after a single dose.Clinical trial identif...
Source: Clinical Drug Investigation - March 31, 2021 Category: Drugs & Pharmacology Source Type: research

Performance Characteristics of Breezhaler ® and Aerolizer ® in the Real-World Setting
AbstractThe evaluation of errors in use with different inhaler devices is challenging to quantify as there are a number of definitions of critical and non-critical errors with respect to inhaler use; in addition, performance characteristics of the device, such as airflow resistance, can also influence effective use in the real-world setting. Repeated observations and checking/correcting inhaler use are essential to optimise clinical effectiveness of inhaled therapy in patients. Breezhaler® is a single unit-dose dry powder inhaler used in chronic obstructive pulmonary disease and in asthma (budesonide) that has low airf...
Source: Clinical Drug Investigation - March 25, 2021 Category: Drugs & Pharmacology Source Type: research

Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges
AbstractThe COVID-19 pandemic continues to affect millions of people across the world. The current global statistics for the disease are 111 million cases and 2.45 million deaths, with new cases emerging each day. Although several drugs including remdesivir have been approved for emergency use, they remain ineffective in bringing the infection under control. Therefore, there is a need for highly effective and safe vaccines against COVID-19. The recent advancements in mRNA vaccines have catapulted them to be forefront in the race to develop vaccines for COVID-19. Two mRNA vaccines, BNT162b2 and mRNA-1273, developed by Pfize...
Source: Clinical Drug Investigation - March 23, 2021 Category: Drugs & Pharmacology Source Type: research

Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration
ConclusionsRopeginterferon alfa-2b exposure was higher in Japanese subjects than in Caucasian subjects. The increase in ropeginterferon alfa-2b exposure was greater than the dose proportion in the dose range of 100 –300 µg. Ropeginterferon alfa-2b was safe and well tolerated.Clinical Trial RegistrationClinicalTrials.gov identifier NCT03546465, registered on 6 June, 2018. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - March 16, 2021 Category: Drugs & Pharmacology Source Type: research

Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy
ConclusionCompared with aspirin alone, rivaroxaban plus aspirin is cost effective in preventing recurrent cardiovascular events in all patients with CAD or PAD, from the Italian perspective. These results could help clinicians and decision makers to develop improved strategies for cardiovascular disease prevention. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - March 16, 2021 Category: Drugs & Pharmacology Source Type: research

Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
AbstractAmikacin liposome inhalation suspension (ALIS) [Arikayce® Liposomal (EU); Arikayce® (USA)], a liposomal suspension of the aminoglycoside amikacin (590  mg) for nebulization via the Lamira® Nebulizer System, is available as add-on therapy for treatment-refractoryMycobacterium avium complex (MAC) lung disease in adults who have little or no alternative treatment options. Its addition to guideline-based therapy (GBT) significantly improved the likelihood of achieving sputum culture conversion (defined as three consecutive monthly MAC-negative sputum cultures) by month  6 relative to GBT alon...
Source: Clinical Drug Investigation - March 16, 2021 Category: Drugs & Pharmacology Source Type: research

Respiratory Safety of Lemborexant in Healthy Subjects: A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Crossover Study
AbstractBackground and ObjectiveLemborexant is a dual orexin receptor antagonist recently approved in the USA, Japan, and Canada for the treatment of adults with insomnia. Because some pharmacotherapy for insomnia causes respiratory depression, this study assessed the effects of lemborexant treatment on respiratory safety parameters.MethodsThis single-dose, randomized, double-blind, placebo-controlled, three-period crossover study enrolled healthy adult and elderly subjects (n = 17). Subjects were randomized to one of three treatment sequences, each consisting of three treatment periods in which they received a single dose...
Source: Clinical Drug Investigation - March 16, 2021 Category: Drugs & Pharmacology Source Type: research

Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug ‒Drug Interactions
AbstractOveractive bladder (OAB) is a common disorder in the general population, and the prevalence increases with age. Adults with OAB typically have a greater number of comorbid conditions, such as hypertension, depression, and dementia, compared with adults without OAB. Subsequent to an increased number of comorbidities, adults with OAB take a greater number of concomitant medications, which may increase the risk of potentially harmful drug ‒drug interactions. There are two important considerations for many of the medications approved for the treatment of OAB in the USA: anticholinergic burden and potential for drug...
Source: Clinical Drug Investigation - March 12, 2021 Category: Drugs & Pharmacology Source Type: research

Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis
ConclusionsIn pooled, analyzed randomized controlled trials and observational studies, DOACs were associated with better efficacy in early CKD, as well as similar efficacy and safety outcomes to warfarin in patients with CKD stages 4 –5 or dialysis patients. The results of patients with CKD stages 4–5 and dialysis patients were from observational studies. Well-designed randomized controlled trials focused on DOAC use in patients with CKD and dialysis patients are needed.PROSPERO register number: CRD42020150599, 6 February, 2020. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - March 11, 2021 Category: Drugs & Pharmacology Source Type: research

Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects
ConclusionsDespite some limitations (differences in the mean dosages per patient and other side effects not included) this paper provides the first complete meta-analysis on SGAs in variations on metabolic risk profile between start of treatment and end of follow-up, with useful results for clinical practice and possibly for future economic evaluation studies. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - March 9, 2021 Category: Drugs & Pharmacology Source Type: research

Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece
ConclusionEmpagliflozin was estimated to be a highly cost-effective treatment option compared to dapagliflozin for the treatment of T2DM patients with established CVD in Greece. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - March 9, 2021 Category: Drugs & Pharmacology Source Type: research

Safety and Efficacy of Rivaroxaban and Apixaban in Patients with Increased Body Mass: a Systematic Review
ConclusionThe literature reports similar or lower bleeding and thrombotic risk for rivaroxaban and apixaban in patients of increased body mass compared to patients of normal body mass. Future prospective controlled studies are needed to further define guidelines for use in this population. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - March 7, 2021 Category: Drugs & Pharmacology Source Type: research

Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan
ConclusionsAnP was not cost effective compared to nP for PD-L1-positive inoperable TNBC under the Japanese condition. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - March 5, 2021 Category: Drugs & Pharmacology Source Type: research

Overall Efficacy and Safety of Safinamide in Parkinson ’s Disease: A Systematic Review and a Meta-analysis
ConclusionOverall, safinamide is effective in PDwMF patients takingl-dopa both at 100 and 50 mg daily. Evidence for efficacy in early PD is limited. Further trials are needed to better evaluate the anti-dyskinetic properties of safinamide. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - March 5, 2021 Category: Drugs & Pharmacology Source Type: research

Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density
ConclusionsSubjects successfully self-administered abaloparatide-sMTS, which provided a consistent pharmacokinetic profile over 29 days and produced s-PINP increases from baseline similar to that observed in the pivotal trial with abaloparatide-SC. Observed patient experience along with the clinical data support continued clinical development of abaloparatide-sMTS.Trial Registration NumberNCT04366726, Date of registration 04/29/2020, retrospectively registered (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - February 27, 2021 Category: Drugs & Pharmacology Source Type: research

Correction to: The CITIMERIVA Study: CITIcoline plus MEmantine plus RIVAstigmine in Older Patients Affected with Alzheimer ’s Disease
A correction to this paper has been published: https://doi.org/10.1007/s40261-021-01015-8 (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - February 27, 2021 Category: Drugs & Pharmacology Source Type: research

Correction to: Ledipasvir –Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection
The original article can be found online. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - February 23, 2021 Category: Drugs & Pharmacology Source Type: research

Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection
ConclusionTargeted omadacycline use may reduce economic burden associated with hospitalized CABP patients treated with moxifloxacin if it can reduce excess cases of moxifloxacin-associated CDI. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - February 19, 2021 Category: Drugs & Pharmacology Source Type: research

An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - February 19, 2021 Category: Drugs & Pharmacology Source Type: research